Orbital Hemorrhage and Compressive Optic Neuropathy in Patients With Midfacial Fractures Receiving Low-Molecular Weight Heparin Therapy
While the implementation of deep vein thrombosis (DVT) prophylaxis in the hospital setting is a major concern, the use of antithrombotic agents is fraught with a variety of hemorrhagic complications. Due to increasing reports of adverse reactions to unfractionated heparin (UFH), several manufacturers have initiated product recalls. As a result, the use of low-molecular weight heparins (LMWHs) such as enoxaparin has risen substantially. In this paper, 2 orbital hemorrhagic complications in patients receiving enoxaparin therapy will be presented. The incidence of DVT in the OMS patient, recent prophylactic strategies, and their effectiveness will be reviewed.
⁎Formerly, Chief Resident, Oral and Maxillofacial Surgery Department, Thomas Jefferson University Hospital, Philadelphia, PA; Currently, MSD Student in Cancer Research, Oral and Maxillofacial Surgery and Cell Biology Departments, Boston University Medical Center, Boston, MA
†Chairman, Oral and Maxillofacial Surgery Department, Thomas Jefferson University Hospital, Philadelphia, PA
‡Assistant Professor, Oral and Maxillofacial Surgery Department, Thomas Jefferson University Hospital, Philadelphia, PA
§Resident, Oral and Maxillofacial Surgery Department, Thomas Jefferson University Hospital, Philadelphia, PA
¶Associate Professor, Oculoplastic Department, Wills Eye Institute, Philadelphia, PA
Address correspondence and reprint requests to Dr Jamal: Boston University Medical Center, Department of Molecular and Cell Biology, 715 Albany Street, EVANS 401 Boston, MA 02118
ABSTRACT